All lobbying filings

FORBES-TATE

Lobbying for NOVARTIS, INC. · Multinational biopharmaceutical company

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 18, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 1672
Maintaining Investments in New Innovation Act
S 832
EPIC Act of 2025

Lobbying activity 6

Taxation/Internal Revenue Code

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Trade (domestic/foreign)

Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.

Budget/Appropriations

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.

Health Issues

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.